The global live attenuated vaccines market size is calculated at USD 32.17 billion in 2025 and is forecasted to reach around USD 82.63 billion by 2034, accelerating at a CAGR of 11.05% from 2025 to 2034. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Live Attenuated Vaccines Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Live Attenuated Vaccines Market, by Vaccines Type
8.1.1. Monovalent
8.1.1.1. Market Revenue and Forecast
8.1.2. Multivalent
8.1.2.1. Market Revenue and Forecast
9.1. Live Attenuated Vaccines Market, by Indication
9.1.1. Influenza
9.1.1.1. Market Revenue and Forecast
9.1.2. Measles, Mumps & Rubella (MMR)
9.1.2.1. Market Revenue and Forecast
9.1.3. Polio
9.1.3.1. Market Revenue and Forecast
9.1.4. Chickenpox
9.1.4.1. Market Revenue and Forecast
9.1.5. Shingles
9.1.5.1. Market Revenue and Forecast
9.1.6. Rotavirus
9.1.6.1. Market Revenue and Forecast
9.1.7. Others
9.1.7.1. Market Revenue and Forecast
10.1. Live Attenuated Vaccines Market, by Route of Administration
10.1.1. Intramuscular
10.1.1.1. Market Revenue and Forecast
10.1.2. Subcutaneous
10.1.2.1. Market Revenue and Forecast
10.1.3. Oral Attenuated
10.1.3.1. Market Revenue and Forecast
10.1.4. Intranasal Attenuated
10.1.4.1. Market Revenue and Forecast
11.1. Live Attenuated Vaccines Market, by Age Group
11.1.1. Pediatrics
11.1.1.1. Market Revenue and Forecast
11.1.2. Adolescents
11.1.2.1. Market Revenue and Forecast
11.1.3. Adults
11.1.3.1. Market Revenue and Forecast
11.1.4. Geriatric patients
11.1.4.1. Market Revenue and Forecast
12.1. Live Attenuated Vaccines Market, by End-User
12.1.1. Hospitals
12.1.1.1. Market Revenue and Forecast
12.1.2. Clinics
12.1.2.1. Market Revenue and Forecast
12.1.3. Other
12.1.3.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Vaccines Type
13.1.2. Market Revenue and Forecast, by Indication
13.1.3. Market Revenue and Forecast, by Route of Administration
13.1.4. Market Revenue and Forecast, by Age Group
13.1.5. Market Revenue and Forecast, by End-User
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Vaccines Type
13.1.6.2. Market Revenue and Forecast, by Indication
13.1.6.3. Market Revenue and Forecast, by Route of Administration
13.1.6.4. Market Revenue and Forecast, by Age Group
13.1.6.5. Market Revenue and Forecast, by End-User
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Vaccines Type
13.1.7.2. Market Revenue and Forecast, by Indication
13.1.7.3. Market Revenue and Forecast, by Route of Administration
13.1.7.4. Market Revenue and Forecast, by Age Group
13.1.7.5. Market Revenue and Forecast, by End-User
13.2. Europe
13.2.1. Market Revenue and Forecast, by Vaccines Type
13.2.2. Market Revenue and Forecast, by Indication
13.2.3. Market Revenue and Forecast, by Route of Administration
13.2.4. Market Revenue and Forecast, by Age Group
13.2.5. Market Revenue and Forecast, by End-User
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Vaccines Type
13.2.6.2. Market Revenue and Forecast, by Indication
13.2.6.3. Market Revenue and Forecast, by Route of Administration
13.2.7. Market Revenue and Forecast, by Age Group
13.2.8. Market Revenue and Forecast, by End-User
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Vaccines Type
13.2.9.2. Market Revenue and Forecast, by Indication
13.2.9.3. Market Revenue and Forecast, by Route of Administration
13.2.10. Market Revenue and Forecast, by Age Group
13.2.11. Market Revenue and Forecast, by End-User
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Vaccines Type
13.2.12.2. Market Revenue and Forecast, by Indication
13.2.12.3. Market Revenue and Forecast, by Route of Administration
13.2.12.4. Market Revenue and Forecast, by Age Group
13.2.13. Market Revenue and Forecast, by End-User
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Vaccines Type
13.2.14.2. Market Revenue and Forecast, by Indication
13.2.14.3. Market Revenue and Forecast, by Route of Administration
13.2.14.4. Market Revenue and Forecast, by Age Group
13.2.15. Market Revenue and Forecast, by End-User
13.3. APAC
13.3.1. Market Revenue and Forecast, by Vaccines Type
13.3.2. Market Revenue and Forecast, by Indication
13.3.3. Market Revenue and Forecast, by Route of Administration
13.3.4. Market Revenue and Forecast, by Age Group
13.3.5. Market Revenue and Forecast, by End-User
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Vaccines Type
13.3.6.2. Market Revenue and Forecast, by Indication
13.3.6.3. Market Revenue and Forecast, by Route of Administration
13.3.6.4. Market Revenue and Forecast, by Age Group
13.3.7. Market Revenue and Forecast, by End-User
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Vaccines Type
13.3.8.2. Market Revenue and Forecast, by Indication
13.3.8.3. Market Revenue and Forecast, by Route of Administration
13.3.8.4. Market Revenue and Forecast, by Age Group
13.3.9. Market Revenue and Forecast, by End-User
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Vaccines Type
13.3.10.2. Market Revenue and Forecast, by Indication
13.3.10.3. Market Revenue and Forecast, by Route of Administration
13.3.10.4. Market Revenue and Forecast, by Age Group
13.3.10.5. Market Revenue and Forecast, by End-User
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Vaccines Type
13.3.11.2. Market Revenue and Forecast, by Indication
13.3.11.3. Market Revenue and Forecast, by Route of Administration
13.3.11.4. Market Revenue and Forecast, by Age Group
13.3.11.5. Market Revenue and Forecast, by End-User
13.4. MEA
13.4.1. Market Revenue and Forecast, by Vaccines Type
13.4.2. Market Revenue and Forecast, by Indication
13.4.3. Market Revenue and Forecast, by Route of Administration
13.4.4. Market Revenue and Forecast, by Age Group
13.4.5. Market Revenue and Forecast, by End-User
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Vaccines Type
13.4.6.2. Market Revenue and Forecast, by Indication
13.4.6.3. Market Revenue and Forecast, by Route of Administration
13.4.6.4. Market Revenue and Forecast, by Age Group
13.4.7. Market Revenue and Forecast, by End-User
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Vaccines Type
13.4.8.2. Market Revenue and Forecast, by Indication
13.4.8.3. Market Revenue and Forecast, by Route of Administration
13.4.8.4. Market Revenue and Forecast, by Age Group
13.4.9. Market Revenue and Forecast, by End-User
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Vaccines Type
13.4.10.2. Market Revenue and Forecast, by Indication
13.4.10.3. Market Revenue and Forecast, by Route of Administration
13.4.10.4. Market Revenue and Forecast, by Age Group
13.4.10.5. Market Revenue and Forecast, by End-User
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Vaccines Type
13.4.11.2. Market Revenue and Forecast, by Indication
13.4.11.3. Market Revenue and Forecast, by Route of Administration
13.4.11.4. Market Revenue and Forecast, by Age Group
13.4.11.5. Market Revenue and Forecast, by End-User
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Vaccines Type
13.5.2. Market Revenue and Forecast, by Indication
13.5.3. Market Revenue and Forecast, by Route of Administration
13.5.4. Market Revenue and Forecast, by Age Group
13.5.5. Market Revenue and Forecast, by End-User
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Vaccines Type
13.5.6.2. Market Revenue and Forecast, by Indication
13.5.6.3. Market Revenue and Forecast, by Route of Administration
13.5.6.4. Market Revenue and Forecast, by Age Group
13.5.7. Market Revenue and Forecast, by End-User
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Vaccines Type
13.5.8.2. Market Revenue and Forecast, by Indication
13.5.8.3. Market Revenue and Forecast, by Route of Administration
13.5.8.4. Market Revenue and Forecast, by Age Group
13.5.8.5. Market Revenue and Forecast, by End-User
14.1. Merck & Co., Inc.
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. GlaxoSmithKline plc
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Pfizer Inc.
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Sanofi
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Johnson & Johnson
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Astellas Pharma
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. CSL Limited
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Serum Institute of India Pvt. Ltd.
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. CARITAS
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample